AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

Pharmaceutical stocks can bring an element of safety to your portfolio. All of this equals a rather steady stream of revenue ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with ...

RFK Jr.'s call to ban TV advertisements for prescription drugs reignited support for a bipartisan bill that would mandate the retail prices of drugs be included in TV ads.

To corral costs, Keith is leading a new initiative at BCBSM called Blue Cross Accelerated that aims to cut $600 million in ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a host of cheaper biosimilars to hit the market. Sales of AbbVie’s Humira (adalimumab ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...